AAPLOG’s amicus brief in Danco v. Louisiana and GenBioPro v. Louisiana filed May 6th affirms that women deserve real medicine, not a mail-order workaround that benefits only the abortion industry. Urging the Supreme Court to leave the Fifth Circuit’s ruling in place (which would immediately reinstate the in-person dispensing requirement for the abortion drug mifepristone), the brief shows that ACOG’s claims to courts about the safety of mail-order abortion are contradicted by ACOG’s own clinical bulletins and by the FDA studies the agency itself relied on. Most of those studies still required in-person evaluation, none offered a statistically significant comparison of wholly remote abortion and most found higher emergency room visits than prior labeling disclosed.
Reinstating the pre-2023 requirement for an in-person evaluation before mifepristone is dispensed is a bare minimum safety standard and is best for the health and safety of both our maternal and preborn patients.